Aspira Pathlab & Diagnostics Ltd
Incorporated in 1973, Aspira Pathlab & Diagnostics Ltd is in the business of pathology and related healthcare services[1]
- Market Cap ₹ 130 Cr.
- Current Price ₹ 126
- High / Low ₹ 150 / 49.0
- Stock P/E 54.1
- Book Value ₹ 7.02
- Dividend Yield 0.00 %
- ROCE 17.0 %
- ROE 33.0 %
- Face Value ₹ 10.0
Pros
- Debtor days have improved from 50.5 to 39.0 days.
- Company's working capital requirements have reduced from 19.6 days to 14.1 days
Cons
- Stock is trading at 18.0 times its book value
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Service Provider
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|
| 13.20 | 22.00 | 22.62 | |
| 14.38 | 18.49 | 19.15 | |
| Operating Profit | -1.18 | 3.51 | 3.47 |
| OPM % | -8.94% | 15.95% | 15.34% |
| 0.42 | 0.36 | 0.41 | |
| Interest | 0.37 | 0.35 | 0.00 |
| Depreciation | 1.54 | 1.49 | 1.49 |
| Profit before tax | -2.67 | 2.03 | 2.39 |
| Tax % | 0.00% | 0.00% | |
| -2.67 | 2.02 | 2.40 | |
| EPS in Rs | -2.59 | 1.96 | 2.33 |
| Dividend Payout % | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 67% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 177% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 11% |
| 3 Years: | 52% |
| 1 Year: | 96% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 33% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| Equity Capital | 10.29 | 10.29 |
| Reserves | -5.08 | -3.06 |
| 7.71 | 8.13 | |
| 1.79 | 2.11 | |
| Total Liabilities | 14.71 | 17.47 |
| 6.79 | 6.53 | |
| CWIP | 0.00 | 0.00 |
| Investments | 0.00 | 0.08 |
| 7.92 | 10.86 | |
| Total Assets | 14.71 | 17.47 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| 1.05 | 1.83 | |
| 0.14 | 0.12 | |
| -0.95 | -0.99 | |
| Net Cash Flow | 0.24 | 0.95 |
| Free Cash Flow | 0.79 | 1.66 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | -89% | 52% |
Ratios
Consolidated / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| Debtor Days | 61.94 | 38.99 |
| Inventory Days | 62.69 | 50.31 |
| Days Payable | 101.70 | 73.00 |
| Cash Conversion Cycle | 22.93 | 16.30 |
| Working Capital Days | 25.16 | 14.10 |
| ROCE % | 17.04% |
Insights
In beta| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Number of Permanent Employees employees ・Standalone data |
|
||||||
| B2B Revenue Share % of revenue ・Standalone data |
|||||||
Extracted by Screener AI
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
- Compliance Certificate under reg 74(5) of SEBI (DP) regulation, 2018 for the quarter ended September 30, 2026.
-
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
- Promoter Jay Arvind Bhanushali acquired 245 shares on 28-09-2026; holding rose to 7.28%.
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
-
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
- 53rd AGM resolutions passed; voting results filed on 25 Sep 2026, including Nikunj Mange reappointment and redesignation.
- Shareholder Meeting / Postal Ballot-Outcome of AGM
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
Business Overview:[1][2][3]
Aspira Pathlab & Diagnostics Ltd (APDL) provides pathology and radiology investigation services through diagnostic centers in Mumbai. Serving B2B and B2C markets, the company offers diagnostic solutions to individual patients, hospitals, healthcare providers, and businesses.